Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Show more
Location: 116 Huntington Avenue, Boston, MA, 02116, United States | Website: https://www.bicara.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
654.8M
52 Wk Range
$7.80 - $28.09
Previous Close
$12.00
Open
$11.98
Volume
199,254
Day Range
$11.56 - $12.12
Enterprise Value
219.6M
Cash
436.6M
Avg Qtr Burn
-25.24M
Insider Ownership
12.23%
Institutional Own.
93.88%
Qtr Updated
06/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Ficerafusp alfa + Pembrolizumab Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Phase 2/3 Data readout | |
Ficerafusp alfa -/+ Pembrolizumab Details 3L+ metastatic colorectal cancer (RAS/B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type) | Phase 1b Initiation | |
Ficerafusp alfa Details 1L recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) | Phase 1 Data readout |